Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EPRX Eupraxia Pharmaceuticals	$5.38 +1.5%	$5.12	$2.20 ▼ $6.20	$190.59M	1.5	11,055 shs	10,344 shs
HRTX Heron Therapeutics	$1.29 -0.8%	$1.91	$1.04 ▼ $2.68	$199.28M	1.15	2.23 million shs	1.40 million shs
MNPR Monopar Therapeutics	$33.51 -2.2%	$38.01	$2.15 ▼ $54.30	$211.38M	1.05	20,432 shs	40,492 shs
PYRGF PyroGenesis Canada	$0.23 -5.6%	$0.31	$0.23 ▼ $0.71	$42.89M	0.83	12,932 shs	31,783 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EPRX Eupraxia Pharmaceuticals	-0.38%	-0.38%	+0.19%	+35.90%	+107.84%
HRTX Heron Therapeutics	-2.26%	+1.56%	-32.64%	-32.29%	-32.64%
MNPR Monopar Therapeutics	-4.06%	+9.32%	-26.29%	-7.15%	+1,370.39%
PYRGF PyroGenesis Canada	-6.12%	-8.53%	-25.33%	-25.67%	-59.54%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EPRX Eupraxia Pharmaceuticals	1.9831 of 5 stars	3.6	1.0	0.0	0.0	1.6	0.0	0.6
HRTX Heron Therapeutics	4.2468 of 5 stars	3.2	1.0	0.0	4.2	4.1	3.3	0.6
MNPR Monopar Therapeutics	2.8794 of 5 stars	3.4	4.0	0.0	0.0	2.6	2.5	0.0
PYRGF PyroGenesis Canada	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EPRX Eupraxia Pharmaceuticals	3.17	Buy	$11.00	104.46% Upside
HRTX Heron Therapeutics	2.33	Hold	$4.50	248.84% Upside
MNPR Monopar Therapeutics	2.83	Moderate Buy	$60.00	79.05% Upside
PYRGF PyroGenesis Canada	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest PYRGF, HRTX, MNPR, and EPRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	MNPR Monopar Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00
8/12/2025	HRTX Heron Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell
8/8/2025	HRTX Heron Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$4.00 ➝ $3.00
7/24/2025	EPRX Eupraxia Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$11.00
7/7/2025	MNPR Monopar Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$74.00
6/26/2025	EPRX Eupraxia Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
6/26/2025	EPRX Eupraxia Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
6/23/2025	MNPR Monopar Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$60.00
6/16/2025	EPRX Eupraxia Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Speculative Buy
6/9/2025	HRTX Heron Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$6.00

(Data available from 8/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	($0.30) per share	N/A
HRTX Heron Therapeutics	$144.29M	1.37	N/A	N/A	($0.18) per share	-7.17
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	$8.46 per share	N/A
PYRGF PyroGenesis Canada	$9.14M	4.69	N/A	N/A	($0.01) per share	-22.87

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EPRX Eupraxia Pharmaceuticals	-$25.50M	-$0.85	0.00	N/A	N/A	N/A	-367.73%	-126.38%	11/6/2025 (Estimated)
HRTX Heron Therapeutics	-$13.58M	-$0.02	0.00	N/A	N/A	-0.62%	N/A	-0.40%	N/A
MNPR Monopar Therapeutics	-$15.59M	-$3.33	0.00	N/A	N/A	N/A	-41.76%	-39.49%	N/A
PYRGF PyroGenesis Canada	-$21.12M	-$0.03	N/A	∞	N/A	-115.14%	N/A	-60.81%	N/A

Latest PYRGF, HRTX, MNPR, and EPRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	EPRX Eupraxia Pharmaceuticals	-$0.21	-$0.26	-$0.05	-$0.26	N/A	N/A
8/12/2025	Q2 2025	MNPR Monopar Therapeutics	-$0.47	-$0.35	+$0.12	-$0.35	N/A	N/A
8/8/2025	Q2 2025	HRTX Heron Therapeutics	-$0.01	-$0.02	-$0.01	-$0.02	$38.08 million	$37.20 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
HRTX Heron Therapeutics	N/A	N/A	N/A	N/A	N/A
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	N/A
PYRGF PyroGenesis Canada	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EPRX Eupraxia Pharmaceuticals	N/A	8.72	8.72
HRTX Heron Therapeutics	N/A	0.82	0.53
MNPR Monopar Therapeutics	N/A	33.93	33.93
PYRGF PyroGenesis Canada	N/A	0.60	0.50

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EPRX Eupraxia Pharmaceuticals	N/A
HRTX Heron Therapeutics	80.01%
MNPR Monopar Therapeutics	1.83%
PYRGF PyroGenesis Canada	0.03%

Insider Ownership

Company	Insider Ownership
EPRX Eupraxia Pharmaceuticals	N/A
HRTX Heron Therapeutics	5.86%
MNPR Monopar Therapeutics	20.50%
PYRGF PyroGenesis Canada	47.68%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EPRX Eupraxia Pharmaceuticals	29	35.96 million	N/A	N/A
HRTX Heron Therapeutics	300	153.29 million	144.31 million	Optionable
MNPR Monopar Therapeutics	10	6.17 million	4.91 million	Not Optionable
PYRGF PyroGenesis Canada	90	187.53 million	96.34 million	No Data

PYRGF, HRTX, MNPR, and EPRX Headlines

Recent News About These Companies

PyroGenesis Announces Second Quarter 2025 Results

August 6, 2025 | globenewswire.com

PyroGenesis Signs Additional Contract with Constellium to Advance Aluminum Furnace Electrification Using Plasma Torch Technology

August 5, 2025 | globenewswire.com

PyroGenesis Canada (NASDAQ:PYRGF) Stock Price Down 1% - Here's What Happened

August 3, 2025 | marketbeat.com

PyroGenesis Schedules Second Quarter 2025 Financial Results and Business Update Conference Call

August 1, 2025 | globenewswire.com

PyroGenesis Receives Initial Contract for Titanium Metal Powder from European Additive Manufacturing Company

July 31, 2025 | globenewswire.com

PyroGenesis Confirms Third-Party SEM Analysis Supports Pilot-Scale Fumed Silica Morphology Consistent with Commercial-Grade Fumed Silica

July 28, 2025 | globenewswire.com

PyroGenesis Announces Completion of Coke-Oven Gas Valorization and Hydrogen Production Project for Tata Steel

July 15, 2025 | globenewswire.com

PyroGenesis Improves Fumed Silica Quality, Purity, and Consistency Across Multiple Production Cycles

July 8, 2025 | globenewswire.com

PyroGenesis Signs $600,000 Contract Targeting Plastic Waste Management Problem in Europe

July 2, 2025 | globenewswire.com

PyroGenesis Reports Voting Results from 2025 Annual Meeting of Shareholders - Morningstar

June 29, 2025 | morningstar.comM

PyroGenesis Reports Voting Results from 2025 Annual Meeting of Shareholders

June 27, 2025 | globenewswire.com

PyroGenesis Confirms Verification of Fumed Silica Samples by Leading Global Supplier

June 12, 2025 | globenewswire.com

PyroGenesis Announces Extension to Term of Warrants

June 9, 2025 | globenewswire.com

High-Tech Micro Cap Rallies After Securing Boeing Supplier Status

May 29, 2025 | msn.com

PyroGenesis Confirms Receiving Accelerated Customer Request for Fumed Silica Samples

May 28, 2025 | globenewswire.com

PyroGenesis Confirms Production of Fumed Silica at Pilot Scale Following Independent Analysis

May 21, 2025 | globenewswire.com

PyroGenesis Confirms Successful Collection of Material from Fumed Silica Pilot Plant Baghouse

May 15, 2025 | globenewswire.com

PyroGenesis, Inc. (PYRGF) Q1 2025 Earnings Call Transcript

May 14, 2025 | seekingalpha.com

PyroGenesis Announces First Quarter 2025 Results

May 13, 2025 | globenewswire.com

PyroGenesis Provides Update on Fumed Silica Project

May 13, 2025 | globenewswire.com

PyroGenesis Closes $2,385,000 First Tranche in Previously Announced Loan

May 12, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PYRGF, HRTX, MNPR, and EPRX Company Descriptions

Eupraxia Pharmaceuticals NASDAQ:EPRX

$5.38 +0.08 (+1.51%)

As of 04:00 PM Eastern

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.

Heron Therapeutics NASDAQ:HRTX

$1.29 -0.01 (-0.77%)

Closing price 04:00 PM Eastern

Extended Trading

$1.30 +0.01 (+1.16%)

As of 07:24 PM Eastern

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Monopar Therapeutics NASDAQ:MNPR

$33.51 -0.75 (-2.19%)

Closing price 04:00 PM Eastern

Extended Trading

$34.55 +1.04 (+3.10%)

As of 06:08 PM Eastern

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

PyroGenesis Canada NASDAQ:PYRGF

$0.23 -0.01 (-5.61%)

As of 03:52 PM Eastern

PyroGenesis Canada Inc. designs, develops, manufactures, and commercializes plasma processes and solutions worldwide. The company offers DROSRITE, a process for enhancing metal recovery from dross without any hazardous by-products; plasma atomization process that allows produce and sell high purity spherical metal powders; PUREVAP, a process to produce high purity metallurgical and solar grade silicon from quartz; and PUREVAP NSiR, which is designed to transform silicon into spherical silicon nano powders and nanowires for use in lithium-ion batteries. It provides plasma torches and plasma torch systems used toreplace fossil fuel burners in industrial iron ore pelletization process; plasma arc waste destruction systems for waste destruction onboard ships; steam plasma arc refrigerant cracking systems for the destruction of certain refrigerants, including chlorofluorocarbons, hydrofluorocarbons, and hydrochlorofluorocarbons; plasma arc chemical warfare agent destruction systems, which are mobile platforms for the onsite destruction of chemical warfare agents; plasma resource recovery systems for land-based waste destruction and waste-to-energy applications; plasma torches for waste gasification and combustion; and plasma arc gasification and vitrification. In addition, it offers engineering and manufacturing expertise, and contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (including 3D printing), oil and gas, and environmental industries. Further, the company provides installation, commissioning, and start-up services. PyroGenesis Canada Inc. is headquartered in Montreal, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time